Latest News

The newly accredited program will deliver an extensive curriculum covering trauma and emergency management, sports injuries, joint replacement surgeries, and pediatric orthopedic care.

The project will generate between 500 and 700 direct jobs and feature advanced digital infrastructure to ensure operational efficiency, traceability, and robust quality control.

Avéli® stands out as the first and only U.S. FDA-cleared device designed to identify and precisely release the fibrous septae responsible for cellulite dimpling.

This partnership marks a major step in advancing clinical excellence, operational efficiency, and innovation in one of the Middle East’s most rapidly evolving medical markets.

The newly constructed, purpose-built facility is designed to handle high potency drugs, including oncology and hormone products.

The biotechnology market was valued at USD 1.6 trillion in 2020 and is expected to grow at a compound annual growth rate of 14.2%, reaching USD 4.05 trillion by 2035.

These landmark achievements highlight AMCE’s growing capability to deliver complex, life-saving procedures within Africa, reducing the long-standing need for patients to travel abroad for advanced medical treatments.

Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.

This new alliance stands out as a bold and unconventional initiative that blends healthcare innovation with creative design thinking.

The study compared the drug against bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who had not received prior treatment and did not have 17p deletions.